stockportfolio.pro
Stocks / CABA vs PRME
CABA vs PRME
Cabaletta Bio, Inc. and Prime Medicine, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Cabaletta Bio, Inc. (CABA) | Prime Medicine, Inc. (PRME) | |
|---|---|---|
| Market cap | $0.5B | $0.5B |
| Revenue (latest FY) | $0 | $4.63M |
| Net income (latest FY) | $-167.86M | $-201.14M |
| Revenue growth (5y CAGR) | — | -2.3% |
| Net margin | — | -4342.4% |
| Return on equity | -149.8% | -166.4% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CABA — free Open PRME — freeFrequently asked questions
Which is bigger, CABA or PRME?
Cabaletta Bio, Inc. is larger by market capitalization — $0.5B versus $0.5B.
Which grows faster, CABA or PRME?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.